Jill Yarbrough

481 total citations · 1 hit paper
13 papers, 344 citations indexed

About

Jill Yarbrough is a scholar working on Hematology, Nephrology and Physiology. According to data from OpenAlex, Jill Yarbrough has authored 13 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 4 papers in Nephrology and 4 papers in Physiology. Recurrent topics in Jill Yarbrough's work include Platelet Disorders and Treatments (5 papers), Renal Diseases and Glomerulopathies (4 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Jill Yarbrough is often cited by papers focused on Platelet Disorders and Treatments (5 papers), Renal Diseases and Glomerulopathies (4 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Jill Yarbrough collaborates with scholars based in United States, United Kingdom and Japan. Jill Yarbrough's co-authors include Lucielle Mansfield, L A Dykstra, Mitchell J. Picker, Yusuke Suzuki, Jonathan Barratt, Mohit Mathur, Robert W. McNutt, K J Chang, Mark A. Smith and Drake Morgan and has published in prestigious journals such as New England Journal of Medicine, Journal of Pharmacology and Experimental Therapeutics and Psychopharmacology.

In The Last Decade

Jill Yarbrough

13 papers receiving 320 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy

2023 100 citations Mohit Mathur, Jonathan Barratt et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jill Yarbrough United States	7	131	105	95	84	64	13	344
K.-G. Fischer Germany	10	88 0.7×	61 0.6×	27 0.3×	163 1.9×	31 0.5×	13	369
Nilofar Khan India	5	18 0.1×	18 0.2×	22 0.2×	139 1.7×	26 0.4×	12	267
Kazuwa Nakao Japan	8	30 0.2×	37 0.4×	29 0.3×	149 1.8×	67 1.0×	13	372
Selçuk Daşdemir Türkiye	12	26 0.2×	22 0.2×	16 0.2×	175 2.1×	35 0.5×	24	380
Olga Beltcheva Bulgaria	8	177 1.4×	18 0.2×	47 0.5×	166 2.0×	14 0.2×	18	314
Halûk Yavuz Türkiye	8	9 0.1×	21 0.2×	15 0.2×	88 1.0×	22 0.3×	14	245
Melanie Chan United Kingdom	9	57 0.4×	19 0.2×	20 0.2×	96 1.1×	37 0.6×	17	290
Amali Mallawaarachchi Australia	13	124 0.9×	38 0.4×	9 0.1×	300 3.6×	28 0.4×	28	457
Christopher J. Passero United States	8	63 0.5×	29 0.3×	10 0.1×	367 4.4×	127 2.0×	8	425

Countries citing papers authored by Jill Yarbrough

Since Specialization

Citations

This map shows the geographic impact of Jill Yarbrough's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jill Yarbrough with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jill Yarbrough more than expected).

Fields of papers citing papers by Jill Yarbrough

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jill Yarbrough. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jill Yarbrough. The network helps show where Jill Yarbrough may publish in the future.

Co-authorship network of co-authors of Jill Yarbrough

This figure shows the co-authorship network connecting the top 25 collaborators of Jill Yarbrough. A scholar is included among the top collaborators of Jill Yarbrough based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jill Yarbrough. Jill Yarbrough is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

McCafferty, Kieran, Yusuke Suzuki, Adrian Liew, et al.. (2024). #2547 Humoral response to COVID vaccine and infection is intact during sibeprenlimab treatment of IgAN: data from the ENVISION trial. Nephrology Dialysis Transplantation. 39(Supplement_1). 1 indexed citations

Zhang, Xiaoyan, Yanlin Wang, Jill Yarbrough, et al.. (2023). Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Sibeprenlimab in Healthy Participants. Clinical Pharmacology in Drug Development. 12(12). 1211–1220. 2 indexed citations

Mathur, Mohit, Jonathan Barratt, Bobby Chacko, et al.. (2023). A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. New England Journal of Medicine. 390(1). 20–31. 100 indexed citations breakdown →

McCafferty, Kieran, Marcela F. Pasetti, Asher D. Schachter, et al.. (2023). #3347 COVID VACCINE RESPONSES DURING SIBEPRENLIMAB TREATMENT OF IGA NEPHROPATHY (IGAN): AN INTERIM ANALYSIS. Nephrology Dialysis Transplantation. 38(Supplement_1). 5 indexed citations

Mathur, Mohit, Jonathan Barratt, Yusuke Suzuki, et al.. (2022). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney International Reports. 7(5). 993–1003. 28 indexed citations

Suzuki, Yusuke, Mohit Mathur, Jonathan Barratt, et al.. (2021). MO258SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY. Nephrology Dialysis Transplantation. 36(Supplement_1). 6 indexed citations

Picker, Mitchell J., Jill Yarbrough, Christine E. Hughes, et al.. (1993). Agonist and antagonist effects of mixed action opioids in the pigeon drug discrimination procedure: influence of training dose, intrinsic efficacy and interanimal differences.. Journal of Pharmacology and Experimental Therapeutics. 266(2). 756–767. 54 indexed citations

Dykstra, L A, et al.. (1993). A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration.. Journal of Pharmacology and Experimental Therapeutics. 267(2). 875–882. 50 indexed citations

Yarbrough, Jill, et al.. (1992). In vitro effects of interleukin-2 and gamma globulin on immune dysfunction in a patient with severe mucocutaneous herpes simplex virus infection.. PubMed. 68(1). 47–52. 1 indexed citations

10.

Picker, Mitchell J. & Jill Yarbrough. (1991). Cross-tolerance and enhanced sensitivity to the response rate-decreasing effects of opioids with varying degrees of efficacy at the mu receptor. Psychopharmacology. 105(4). 459–466. 14 indexed citations

11.

Yarbrough, Jill, John E. Moffitt, Dorothy A. Brown, & Chester T. Stafford. (1989). Cimetidine in the treatment of refractory anaphylaxis.. PubMed. 63(3). 235–8. 21 indexed citations

12.

Yarbrough, Jill, et al.. (1985). Metered dose inhaler induced bronchospasm in asthmatic patients.. PubMed. 55(1). 25–7. 56 indexed citations

13.

Yarbrough, Jill, et al.. (1984). Cromolyn modifies histamine bronchial reactivity in symptomatic seasonal asthma.. PubMed. 52(6). 401–5. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact